ACAD
32.59
-0.76
-2.28%
AEMD
0.227
-0.013
-5.417%
APRI
1.87
-0.05
-2.60%
ARNA
4.37
-0.11
-2.46%
ATEC
1.45
+0.04
+2.84%
CNAT
7.12
-0.41
-5.44%
CRXM
0.195
0.00
0.00%
CYTX
1.18
-0.02
-1.67%
DXCM
62.34
+0.36
+0.58%
GNMK
12.98
-0.32
-2.41%
HALO
14.28
+0.28
+2.00%
ILMN
185.64
-1.98
-1.06%
INNV
0.14
-0.04
-21.74%
INO
8.16
-0.17
-2.04%
ISCO
0.058
-0.001
-1.1966%
ISIS
63.67
-1.14
-1.76%
LGND
77.11
+0.88
+1.15%
LPTN
2.47
0.00
0.00%
MBVX
1.87
+0.01
+0.54%
MEIP
1.79
+0.04
+2.29%
MNOV
3.5
-0.09
-2.51%
MRTX
29.32
+0.21
+0.72%
MSTX
0.485
-0.012
-2.513%
NBIX
39.71
-1.82
-4.38%
NUVA
45.99
-0.41
-0.88%
ONCS
0.335
-0.015
-4.286%
ONVO
3.54
+0.17
+5.04%
OREX
7.83
+0.08
+1.03%
OTIC
35.36
-0.27
-0.76%
QDEL
26.98
-0.52
-1.89%
RCPT
164.89
+4.84
+3.02%
RGLS
16.94
-0.32
-1.85%
RMD
71.78
+0.13
+0.18%
SCIE
0.03
0.00
+17.65%
SPHS
0.579
+0.029
+5.2545%
SRNE
11.56
+0.2
+1.76%
TROV
6.81
-0.19
-2.71%
VICL
0.945
+0.045
+4.9889%
VOLC
17.99
0.00
0.00%
ZGNX
1.37
0.00
0.00%
ACAD
32.59
-0.76
-2.28%
AEMD
0.227
-0.013
-5.417%
APRI
1.87
-0.05
-2.60%
ARNA
4.37
-0.11
-2.46%
ATEC
1.45
+0.04
+2.84%
CNAT
7.12
-0.41
-5.44%
CRXM
0.195
0.00
0.00%
CYTX
1.18
-0.02
-1.67%
DXCM
62.34
+0.36
+0.58%
GNMK
12.98
-0.32
-2.41%
HALO
14.28
+0.28
+2.00%
ILMN
185.64
-1.98
-1.06%
INNV
0.14
-0.04
-21.74%
INO
8.16
-0.17
-2.04%
ISCO
0.058
-0.001
-1.1966%
ISIS
63.67
-1.14
-1.76%
LGND
77.11
+0.88
+1.15%
LPTN
2.47
0.00
0.00%
MBVX
1.87
+0.01
+0.54%
MEIP
1.79
+0.04
+2.29%
MNOV
3.5
-0.09
-2.51%
MRTX
29.32
+0.21
+0.72%
MSTX
0.485
-0.012
-2.513%
NBIX
39.71
-1.82
-4.38%
NUVA
45.99
-0.41
-0.88%
ONCS
0.335
-0.015
-4.286%
ONVO
3.54
+0.17
+5.04%
OREX
7.83
+0.08
+1.03%
OTIC
35.36
-0.27
-0.76%
QDEL
26.98
-0.52
-1.89%
RCPT
164.89
+4.84
+3.02%
RGLS
16.94
-0.32
-1.85%
RMD
71.78
+0.13
+0.18%
SCIE
0.03
0.00
+17.65%
SPHS
0.579
+0.029
+5.2545%
SRNE
11.56
+0.2
+1.76%
TROV
6.81
-0.19
-2.71%
VICL
0.945
+0.045
+4.9889%
VOLC
17.99
0.00
0.00%
ZGNX
1.37
0.00
0.00%
Home » John Finn Biography

John Finn Biography

Dr. Finn holds a B.S. in chemistry from Villanova University and a Ph.D. in organic chemistry from the University of Illinois. He spent the first ten years of his industrial career as doing optimization chemistry for American Cyanamid. In 1995, He moved to Synaptic Pharmaceutical as an associate director of medicinal chemistry at Synaptic Pharmaceutical focusing on drugs targeting novel GPCR targets. From 1998 to 2004, Dr. Finn held various leadership positions at Cubist Pharmaceuticals and Elitra Pharmaceuticals, two biotech companies focusing on novel antibacterial agents. Dr. Finn has served as the chief scientific officer of Trius since February 2007 and is a co-founder of our company. From July 2004 to February 2007, he served as the president.